Amedeo Smart

Free Medical Literature Service


 

Amedeo

Chronic Heart Failure

  Free Subscription

Articles published in
Eur Heart J
    September 2021

  1. Erratum to: CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure.
    Eur Heart J. 2021 Sep 14. pii: 6370281. doi: 10.1093.
    >> Share

  2. JANKOWSKA EA, Ponikowski P
    Intravenous iron supplementation: novel anti-remodelling therapy for patients with heart failure?
    Eur Heart J. 2021 Sep 14. pii: 6370026. doi: 10.1093.
    >> Share

  3. BAYES-GENIS A, Diez J
    Transition to heart failure in hypertension: going to the heart of the matter.
    Eur Heart J. 2021 Sep 13. pii: 6369562. doi: 10.1093.
    >> Share

  4. LEWIS EF
    A fourth pillar for all in the treatment of heart failure.
    Eur Heart J. 2021 Sep 13. pii: 6369563. doi: 10.1093.
    >> Share

  5. KAHN M, Grayson AD, Chaggar PS, Ng Kam Chuen MJ, et al
    Primary care heart failure service identifies a missed cohort of heart failure patients with reduced ejection fraction.
    Eur Heart J. 2021 Sep 11. pii: 6368904. doi: 10.1093.
    >> Share

  6. BROWN JM, Zhou W, Weber B, Divakaran S, et al
    Low coronary flow relative to myocardial mass predicts heart failure in symptomatic hypertensive patients with no obstructive coronary artery disease.
    Eur Heart J. 2021 Sep 7. pii: 6365821. doi: 10.1093.
    >> Share

    August 2021
  7. YILMAZ MB
    Does early angiography pave the way for improved outcomes in patients with acute heart failure?
    Eur Heart J. 2021 Aug 31. pii: 6360027. doi: 10.1093.
    >> Share

  8. MCDONAGH TA, Metra M, Adamo M, Gardner RS, et al
    2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
    Eur Heart J. 2021 Aug 27. pii: 6358045. doi: 10.1093.
    >> Share

  9. LIGHT PE
    Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure.
    Eur Heart J. 2021 Aug 27. pii: 6358226. doi: 10.1093.
    >> Share

  10. POCOCK SJ, Ferreira JP, Gregson J, Anker SD, et al
    Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial.
    Eur Heart J. 2021 Aug 23. pii: 6356321. doi: 10.1093.
    >> Share

  11. CREA F
    The complex relationship among heart failure, cancer, and lipid lowering, and an update on cardiomyopathies.
    Eur Heart J. 2021;42:3029-3032.
    >> Share

  12. BERGER M, Solelhac G, Roche F, Heinzer R, et al
    Insomnia, a new modifiable risk factor for heart failure?
    Eur Heart J. 2021 Aug 21. pii: 6355986. doi: 10.1093.
    >> Share

  13. WITHAAR C, Lam CSP, Schiattarella GG, de Boer RA, et al
    Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models.
    Eur Heart J. 2021 Aug 20. pii: 6355308. doi: 10.1093.
    >> Share

  14. VOLPE M, Gallo G
    Sacubitril/valsartan for heart failure with preserved ejection fraction and resistant hypertension: one shot for a double strike?
    Eur Heart J. 2021 Aug 15. pii: 6352588. doi: 10.1093.
    >> Share

  15. MAHMOOD A, Ray M, Dobalian A, Ward KD, et al
    Insomnia symptoms and incident heart failure: a population-based cohort study.
    Eur Heart J. 2021 Aug 15. pii: 6352589. doi: 10.1093.
    >> Share

  16. WAGNER JUG, Dimmeler S
    The endothelial niche in heart failure: from development to regeneration.
    Eur Heart J. 2021 Aug 15. pii: 6352586. doi: 10.1093.
    >> Share

  17. JACKSON AM, Jhund PS, Anand IS, Dungen HD, et al
    Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.
    Eur Heart J. 2021 Aug 15. pii: 6352587. doi: 10.1093.
    >> Share

  18. DIVAKARAN S, Nohria A
    Decoding the link between heart failure and incident cancer.
    Eur Heart J. 2021 Aug 14. pii: 6352225. doi: 10.1093.
    >> Share

  19. NICHOLLS M
    New perspectives on heart failure.
    Eur Heart J. 2021 Aug 6. pii: 6343116. doi: 10.1093.
    >> Share

    July 2021
  20. KOSYAKOVSKY LB, Austin PC, Ross HJ, Wang X, et al
    Early invasive coronary angiography and acute ischaemic heart failure outcomes.
    Eur Heart J. 2021 Jul 30. pii: 6331345. doi: 10.1093.
    >> Share

  21. TUAL-CHALOT S, Stellos K
    Drug repurposing to prevent pressure overload-induced cardiac hypertrophy and heart failure.
    Eur Heart J. 2021 Jul 13. pii: 6319852. doi: 10.1093.
    >> Share

  22. DA DALT L, Castiglioni L, Baragetti A, Audano M, et al
    PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction.
    Eur Heart J. 2021 Jul 12. pii: 6319627. doi: 10.1093.
    >> Share


  23. European Heart Journal Team Heart Failure.
    Eur Heart J. 2021 Jul 5. pii: 6314555. doi: 10.1093.
    >> Share

  24. ONO M, Garg S, Onuma Y, Serruys PW, et al
    Coronary artery bypass grafting versus percutaneous coronary intervention in ischaemic heart failure. Can reliable treatment decisions in high-risk patients be based on non-randomized data?
    Eur Heart J. 2021 Jul 1. pii: 6311994. doi: 10.1093.
    >> Share

    June 2021
  25. LAM CSP, Ferreira JP, Pfarr E, Sim D, et al
    Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.
    Eur Heart J. 2021 Jun 29. pii: 6310468. doi: 10.1093.
    >> Share

  26. REN QW, Yu SY, Teng TK, Li X, et al
    Statin associated lower cancer risk and related mortality in patients with heart failure.
    Eur Heart J. 2021 Jun 22. pii: 6307232. doi: 10.1093.
    >> Share

  27. CREA F
    The Universal Definition of Heart Failure, risk prediction in cardiogenic shock, artificial intelligence in cardiac allograft rejection, and the genetics of dilated cardiomyopathy.
    Eur Heart J. 2021;42:2317-2320.
    >> Share

  28. NICHOLLS M
    Recognition for heart failure breakthrough.
    Eur Heart J. 2021 Jun 11. pii: 6296965. doi: 10.1093.
    >> Share

  29. JANKOWSKA EA, Kirwan BA, Kosiborod M, Butler J, et al
    The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study.
    Eur Heart J. 2021 Jun 3. pii: 6291468. doi: 10.1093.
    >> Share

  30. ZANNAD F, Cotter G, Alonso Garcia A, George S, et al
    What can heart failure trialists learn from oncology trialists?
    Eur Heart J. 2021 Jun 2. pii: 6291019. doi: 10.1093.
    >> Share

    May 2021
  31. VOLZ S, Redfors B, Angeras O, Ioanes D, et al
    Long-term mortality in patients with ischaemic heart failure revascularized with coronary artery bypass grafting or percutaneous coronary intervention: insights from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
    Eur Heart J. 2021 May 23. pii: 6282431. doi: 10.1093.
    >> Share

  32. MARSTON NA, Han L, Olivotto I, Day SM, et al
    Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy.
    Eur Heart J. 2021;42:1988-1996.
    >> Share

  33. PORCHER R, Desguerre I, Amthor H, Chabrol B, et al
    Association between prophylactic angiotensin-converting enzyme inhibitors and overall survival in Duchenne muscular dystrophy-analysis of registry data.
    Eur Heart J. 2021;42:1976-1984.
    >> Share

  34. NICHOLLS M
    Telemedicine for chronic heart failure patients.
    Eur Heart J. 2021 May 13. pii: 6274945. doi: 10.1093.
    >> Share

  35. HAMDANI N, Costantino S, Mugge A, Lebeche D, et al
    Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies.
    Eur Heart J. 2021 May 5. pii: 6264879. doi: 10.1093.
    >> Share

    April 2021

  36. Corrigendum to: Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23.
    Eur Heart J. 2021 Apr 24. pii: 6248970. doi: 10.1093.
    >> Share

  37. CREA F
    Emerging causes and risk factors of heart failure: amyloidosis, myocarditis, immune checkpoint inhibitors, air pollution, and visceral adipose tissue.
    Eur Heart J. 2021;42:1533-1537.
    >> Share

  38. RAJAGOPALAN S, Brook RD, Al-Kindi S
    Air pollution and flooding in the lungs: modern insights into ancient problems.
    Eur Heart J. 2021;42:1592-1594.
    >> Share

  39. WITHAAR C, Meems LMG, de Boer RA
    Fighting HFpEF in women: taking aim at belly fat.
    Eur Heart J. 2021;42:1606-1608.
    >> Share

  40. FULLENKAMP DE, Puckelwartz MJ, McNally EM
    Genome-wide association for heart failure: from discovery to clinical use.
    Eur Heart J. 2021 Apr 14. pii: 6225796. doi: 10.1093.
    >> Share


  41. Erratum to: Conducting Clinical Trials in Heart Failure During (and After) the COVID-19 Pandemic: An Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
    Eur Heart J. 2021 Apr 7. pii: 6214477. doi: 10.1093.
    >> Share

  42. BAUERSACHS J
    The struggle towards a Universal Definition of Heart Failure-how to proceed?
    Eur Heart J. 2021 Apr 1. pii: 6206998. doi: 10.1093.
    >> Share

    March 2021
  43. CREA F
    Challenges in heart failure: quality of life, chronic kidney disease, and secondary mitral regurgitation.
    Eur Heart J. 2021;42:1185-1189.
    >> Share

  44. SPERTUS JA
    Quality of life in EMPEROR-Reduced: emphasizing what is important to patients while identifying strategies to support more patient-centred care.
    Eur Heart J. 2021;42:1213-1215.
    >> Share

  45. FUKUOKA R, Kawamura A, Kohsaka S
    Prediction of sudden arrhythmic death in patients with heart failure: towards validation in a worldwide broader range of patients.
    Eur Heart J. 2021 Mar 18. pii: 6177055. doi: 10.1093.
    >> Share

  46. COATS AJS, Anker SD, Baumbach A, Alfieri O, et al
    The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and
    Eur Heart J. 2021 Mar 18. pii: 6174642. doi: 10.1093.
    >> Share

  47. YOUNIS A, Goldenberg I
    Extending the MADIT-ICD benefit score to heterogenous heart failure populations.
    Eur Heart J. 2021 Mar 18. pii: 6177051. doi: 10.1093.
    >> Share

  48. VOLPE M, Patrono C
    The value of sotagliflozin in patients with diabetes and heart failure detracted by an unexpected ending.
    Eur Heart J. 2021 Mar 10. pii: 6168016. doi: 10.1093.
    >> Share

  49. GARNIER S, Harakalova M, Weiss S, Mokry M, et al
    Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23.
    Eur Heart J. 2021 Mar 3. pii: 6157424. doi: 10.1093.
    >> Share

  50. VAN DIEPEN S, Armstrong PW
    Learning whether to subtract beta-blockers: it's about time.
    Eur Heart J. 2021;42:915-918.
    >> Share

    February 2021
  51. VOLPE M, Patrono C
    Iron heart.
    Eur Heart J. 2021;42:809-810.
    >> Share

  52. DIDERIKSEN JR, Christiansen MK, Johansen JB, Nielsen JC, et al
    Long-term outcomes in young patients with atrioventricular block of unknown aetiology.
    Eur Heart J. 2021 Feb 18. pii: 6143533. doi: 10.1093.
    >> Share

  53. VILLRINGER A, Laufs U
    Heart failure, cognition, and brain damage.
    Eur Heart J. 2021 Feb 16. pii: 6139887. doi: 10.1093.
    >> Share

  54. HALLIDAY BP, Senior R, Pennell DJ
    Assessing left ventricular systolic function: from ejection fraction to strain analysis.
    Eur Heart J. 2021;42:789-797.
    >> Share

  55. CREA F
    New guidelines on adult congenital heart disease, the fantastic four in the treatment of heart failure, and also what happened in the last year in heart failure and valvular heart disease.
    Eur Heart J. 2021;42:551-554.
    >> Share


  56. Corrigendum to: The Year in Cardiovascular Medicine: Heart Failure and Cardiomyopathies. The Year in Cardiovascular Medicine 2020.
    Eur Heart J. 2021 Feb 11. pii: 6132731. doi: 10.1093.
    >> Share

  57. PETRIE MC, Lee MM, Lang NN
    EMPEROR-REDUCED reigns while EMPERIAL whimpers.
    Eur Heart J. 2021;42:711-714.
    >> Share

  58. WANG M, Zhou T, Song Y, Li X, et al
    Joint exposure to various ambient air pollutants and incident heart failure: a prospective analysis in UK Biobank.
    Eur Heart J. 2021 Feb 2. pii: 6126215. doi: 10.1093/eurheartj/ehaa1031.
    >> Share

    January 2021
  59. LOCH A, Koh PS, Manokaran P
    Giant hepatic cyst masquerading as right heart failure.
    Eur Heart J. 2021 Jan 30. pii: 6124029. doi: 10.1093.
    >> Share

  60. FREY A, Homola GA, Henneges C, Muhlbauer L, et al
    Temporal changes in total and hippocampal brain volume and cognitive function in patients with chronic heart failure-the COGNITION.MATTERS-HF cohort study.
    Eur Heart J. 2021 Jan 26. pii: 6120261. doi: 10.1093.
    >> Share


  61. Corrigendum to: Does hypoperfusion outperform blood pressure as a better predictor in the risk stratification of acute heart failure?
    Eur Heart J. 2021;42:319.
    >> Share

  62. MASSIMO V, Carlo P
    Truly galactic?
    Eur Heart J. 2021;42:296-297.
    >> Share

  63. EVANS MA, Sano S, Walsh K
    Clonal haematopoiesis and cardiovascular disease: how low can you go?
    Eur Heart J. 2021;42:266-268.
    >> Share

  64. SMISETH OA, Aalen JM, Skulstad H
    Heart failure and systolic function: time to leave diagnostics based on ejection fraction?
    Eur Heart J. 2021 Jan 17. pii: 6075085. doi: 10.1093.
    >> Share

  65. BAUERSACHS J
    Heart failure drug treatment: the fantastic four.
    Eur Heart J. 2021 Jan 14. pii: 6099035. doi: 10.1093/eurheartj/ehaa1012.
    >> Share

  66. CSENGERI D, Sprunker NA, Di Castelnuovo A, Niiranen T, et al
    Alcohol consumption, cardiac biomarkers, and risk of atrial fibrillation and adverse outcomes.
    Eur Heart J. 2021 Jan 13. pii: 6090248. doi: 10.1093.
    >> Share

  67. HOLT A, Blanche P, Zareini B, Rajan D, et al
    Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study.
    Eur Heart J. 2021 Jan 11. pii: 6082772. doi: 10.1093/eurheartj/ehaa1058.
    >> Share

  68. PACKER M, Anker SD, Butler J, Filippatos G, et al
    Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.
    Eur Heart J. 2021 Jan 11. pii: 6081935. doi: 10.1093.
    >> Share

  69. BUTLER J, Anker SD, Filippatos G, Khan MS, et al
    Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.
    Eur Heart J. 2021 Jan 9. pii: 6072066. doi: 10.1093/eurheartj/ehaa1007.
    >> Share

  70. CREA F
    Machine learning-guided phenotyping of dilated cardiomyopathy and treatment of heart failure by antisense oligonucleotides: the future has begun.
    Eur Heart J. 2021;42:139-142.
    >> Share

  71. DEVAUX Y, Badimon L
    CDR132L: another brick in the wall towards the use of miRNAs to treat cardiovascular disease.
    Eur Heart J. 2021;42:202-204.
    >> Share

  72. AGARWAL R, Kolkhof P, Bakris G, Bauersachs J, et al
    Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.
    Eur Heart J. 2021;42:152-161.
    >> Share

  73. FURHOLZ M, Gisler F, Hunziker L, Huber AT, et al
    Posture dependent dynamic external outflow graft compression in HeartMate 3TM left ventricular assist device.
    Eur Heart J. 2021;42:205.
    >> Share

  74. BUENO H, Moura B, Lancellotti P, Bauersachs J, et al
    The year in cardiovascular medicine 2020: heart failure and cardiomyopathies.
    Eur Heart J. 2021 Jan 3. pii: 6060054. doi: 10.1093/eurheartj/ehaa1061.
    >> Share

    December 2020

  75. Corrigendum to: How to Diagnose Heart Failure with Preserved Ejection Fraction - The HFA-PEFF-SCORE An updated Consensus Statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
    Eur Heart J. 2020 Dec 29. pii: 6055039. doi: 10.1093/eurheartj/ehaa1016.
    >> Share

  76. ABRAHAM WT, Lindenfeld J, Ponikowski P, Agostoni P, et al
    Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.
    Eur Heart J. 2020 Dec 22. pii: 6044442. doi: 10.1093.
    >> Share

  77. BAKER AH, Giacca M
    Antagonism of miRNA in heart failure: first evidence in human.
    Eur Heart J. 2020 Dec 18. pii: 6041762. doi: 10.1093.
    >> Share

  78. ROY R, Koch WJ
    Adding another GRK to the fire of heart failure.
    Eur Heart J. 2020 Dec 7. pii: 6025474. doi: 10.1093.
    >> Share

    November 2020
  79. PITT B, Byrd JB
    Detection of patients at risk of developing heart failure responsive to mineralocorticoid receptor antagonists (MRAs): new insights and opportunities.
    Eur Heart J. 2020 Nov 30. pii: 6012925. doi: 10.1093.
    >> Share

  80. ASSMUS B, Cremer S, Kirschbaum K, Culmann D, et al
    Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations.
    Eur Heart J. 2020 Nov 26. pii: 6006386. doi: 10.1093.
    >> Share

  81. SORIMACHI H, Obokata M, Takahashi N, Reddy YNV, et al
    Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction.
    Eur Heart J. 2020 Nov 23. pii: 5998959. doi: 10.1093.
    >> Share

  82. BOHM M, Mahfoud F
    J-curve revisited.
    Eur Heart J. 2020;41:4283.
    >> Share

  83. LIEW CH, McEvoy JW
    The diastolic blood pressure J-curve remains an observational research phenomenon that has not yet been proven as causal and should not be used to make invasive treatment decisions.
    Eur Heart J. 2020;41:4284-4285.
    >> Share

  84. FEDCHENKO M, Mandalenakis Z, Giang KW, Rosengren A, et al
    Long-term outcomes after myocardial infarction in middle-aged and older patients with congenital heart disease-a nationwide study.
    Eur Heart J. 2020 Nov 21. pii: 5997447. doi: 10.1093.
    >> Share

  85. CLELAND JGF, Ferreira JP, Mariottoni B, Pellicori P, et al
    The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.
    Eur Heart J. 2020 Nov 20. pii: 5993916. doi: 10.1093.
    >> Share

  86. ALFONSO F
    Heart Failure 2019.
    Eur Heart J. 2020 Nov 17. pii: 5986679. doi: 10.1093.
    >> Share

  87. TAUBEL J, Hauke W, Rump S, Viereck J, et al
    Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study.
    Eur Heart J. 2020 Nov 11. pii: 5974817. doi: 10.1093.
    >> Share

    October 2020

  88. Corrigendum to: Treatment of heart failure with reduced ejection fraction: the dawn of sodium-glucose cotransporter-2 inhibitors.
    Eur Heart J. 2020 Oct 22. pii: 5935857. doi: 10.1093.
    >> Share

  89. BATKAI S, Genschel C, Viereck J, Rump S, et al
    CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure.
    Eur Heart J. 2020 Oct 22. pii: 5934677. doi: 10.1093.
    >> Share

  90. CREA F
    The multiple causes and treatments of heart failure: focus on genetic and molecular mechanisms and non-pharmacological interventions.
    Eur Heart J. 2020;41:3769-3773.
    >> Share

  91. BONNET M, Champagnac A, Lantelme P, Harbaoui B, et al
    Endomyocardial biopsy findings in Kawasaki-like disease associated with SARS-CoV-2.
    Eur Heart J. 2020;41:3863-3864.
    >> Share

  92. PETTIT SJ
    HeartMate 3: real-world performance matches pivotal trial.
    Eur Heart J. 2020;41:3810-3812.
    >> Share

  93. LIUZZO G, Patrono C
    EMPEROR-Reduced supports the use of SGLT2 inhibitors for the treatment of patients with heart failure and reduced ejection fraction: Comment on the EMPEROR-Reduced trial.
    Eur Heart J. 2020 Oct 7. pii: 5918827. doi: 10.1093.
    >> Share

    September 2020
  94. CREA F
    Treatment of heart failure: the dawn of the era of sodium-glucose co-transporter-2 inhibitors.
    Eur Heart J. 2020;41:3379-3383.
    >> Share


  95. Corrigendum to: Does hypoperfusion outperform blood pressure as a better predictor in the risk stratification of acute heart failure? [Eur Heart J 2020;41: 2411].
    Eur Heart J. 2020 Sep 15. pii: 5906090. doi: 10.1093.
    >> Share

  96. BUTLER J, Zannad F, Filippatos G, Anker SD, et al
    Totality of evidence in trials of sodium-glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice.
    Eur Heart J. 2020 Sep 15. pii: 5906091. doi: 10.1093.
    >> Share

  97. SAVARESE G, Cosentino F
    The interaction between dapagliflozin and blood pressure in heart failure: new evidence dissipating concerns.
    Eur Heart J. 2020 Sep 9. pii: 5903162. doi: 10.1093.
    >> Share

    August 2020
  98. SERENELLI M, Bohm M, Inzucchi SE, Kober L, et al
    Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF).
    Eur Heart J. 2020 Aug 21. pii: 5895186. doi: 10.1093.
    >> Share

    July 2020
  99. HARARI R, Bangalore S
    Beta-blockers after acute myocardial infarction: an old drug in urgent need of new evidence!
    Eur Heart J. 2020 Jul 30. pii: 5879119. doi: 10.1093.
    >> Share

  100. FIGLIOZZI S, Rizzo S, De Gaspari M, Tarantini G, et al
    End-stage heart failure secondary to low-dose hydroxychloroquine treatment.
    Eur Heart J. 2020 Jul 29. pii: 5877566. doi: 10.1093.
    >> Share


  101. Corrigendum to: How to slice the pie: heart failure subgroups and their clinical meaning.
    Eur Heart J. 2020 Jul 25. pii: 5876171. doi: 10.1093.
    >> Share

  102. ESCANED J, Lerman LO
    Coronary microcirculation and hypertensive heart failure.
    Eur Heart J. 2020;41:2376-2378.
    >> Share

  103. LUSCHER TF
    How to slice the pie: heart failure subgroups and their clinical meaning.
    Eur Heart J. 2020;41:2339-2343.
    >> Share

  104. SCHMIDT IM, Verma A, Waikar SS
    Circulating plasma angiotensin-converting enzyme 2 concentrations in patients with kidney disease.
    Eur Heart J. 2020;41:3097-3098.
    >> Share

    June 2020
  105. KARASON K, Jamaly S
    Heart failure development in obesity: mechanistic pathways.
    Eur Heart J. 2020 Jun 18. pii: 5859181. doi: 10.1093.
    >> Share

  106. ZHOU Y, Liu F, Nie J
    Does hypoperfusion outperformed blood pressure as a better predictor in the risk stratification of acute heart failure?
    Eur Heart J. 2020 Jun 18. pii: 5859700. doi: 10.1093.
    >> Share

  107. BOCCHINO PP, Angelini F, Frea S
    Intravenous vasodilators in acute heart failure patients with low basic blood pressure: may the benefit come from targeting perfusion rather than pressure?
    Eur Heart J. 2020 Jun 18. pii: 5859697. doi: 10.1093.
    >> Share

  108. KIM J, Kang D, Park H, Kang M, et al
    Long-term beta-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study.
    Eur Heart J. 2020 Jun 15. pii: 5857797. doi: 10.1093.
    >> Share

  109. ANKER SD, Butler J, Khan MS, Abraham WT, et al
    Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
    Eur Heart J. 2020 Jun 4. pii: 5851435. doi: 10.1093.
    >> Share

  110. CULEBRAS E, Hernandez F
    ACE2 is on the X chromosome: could this explain COVID-19 gender differences?
    Eur Heart J. 2020;41:3095.
    >> Share

    May 2020
  111. PACKER M
    Longevity genes, cardiac ageing, and the pathogenesis of cardiomyopathy: implications for understanding the effects of current and future treatments for heart failure.
    Eur Heart J. 2020 May 27. pii: 5847945. doi: 10.1093.
    >> Share

  112. SAMA IE, Ravera A, Santema BT, van Goor H, et al
    Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors.
    Eur Heart J. 2020;41:1810-1817.
    >> Share

  113. OUDIT GY, Pfeffer MA
    Plasma angiotensin-converting enzyme 2: novel biomarker in heart failure with implications for COVID-19.
    Eur Heart J. 2020;41:1818-1820.
    >> Share

  114. INCIARDI RM, Adamo M, Lupi L, Cani DS, et al
    Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy.
    Eur Heart J. 2020;41:1821-1829.
    >> Share

  115. THUM T
    SARS-CoV-2 receptor ACE2 expression in the human heart: cause of a post-pandemic wave of heart failure?
    Eur Heart J. 2020 May 8. pii: 5834515. doi: 10.1093.
    >> Share

  116. OZKAN J
    Trying times for heart failure trials during the COVID-19 pandemic.
    Eur Heart J. 2020;41:1715.
    >> Share

  117. LUSCHER TF
    Cardio-oncology and the future of heart failure.
    Eur Heart J. 2020;41:1709-1712.
    >> Share

  118. PITT B
    Mark Nicholls speaks to Professor Bertram Pitt and his role as a pioneer in cardiology over the management of heart failure.
    Eur Heart J. 2020;41:1615-1617.
    >> Share

  119. MILLER VM
    Universality of sex differences in cardiovascular outcomes: where do we go from here?
    Eur Heart J. 2020;41:1697-1699.
    >> Share

    April 2020
  120. PACKER M
    Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care.
    Eur Heart J. 2020 Apr 29. pii: 5827051. doi: 10.1093.
    >> Share

  121. BOHM M, Bewarder Y, Kindermann I
    Ejection fraction in heart failure revisited- where does the evidence start?
    Eur Heart J. 2020 Apr 29. pii: 5827050. doi: 10.1093.
    >> Share

  122. BARTKO PE, Hulsmann M, Hung J, Pavo N, et al
    Secondary valve regurgitation in patients with heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, and heart failure with reduced ejection fraction.
    Eur Heart J. 2020 Apr 29. pii: 5827049. doi: 10.1093.
    >> Share

  123. BAYES-GENIS A, Liu PP, Lanfear DE, de Boer RA, et al
    Omics phenotyping in heart failure: the next frontier.
    Eur Heart J. 2020 Apr 26. pii: 5825477. doi: 10.1093.
    >> Share

  124. TAHARA A, Tahara N, Maeda-Ogata S, Bekki M, et al
    Brown adipose tissue activation in severe heart failure.
    Eur Heart J. 2020 Apr 24. pii: 5824912. doi: 10.1093.
    >> Share

  125. LUSCHER TF
    Sex and gender and cardiovascular medicine: impact in diabetes, acute coronary syndromes, and heart failure.
    Eur Heart J. 2020;41:1311-1314.
    >> Share

    March 2020
  126. LAM CSP, Voors AA, Piotr P, McMurray JJV, et al
    Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction.
    Eur Heart J. 2020 Mar 30. pii: 5813810. doi: 10.1093.
    >> Share

  127. VADUGANATHAN M, Jhund PS, Claggett BL, Packer M, et al
    A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction.
    Eur Heart J. 2020 Mar 28. pii: 5813082. doi: 10.1093.
    >> Share

  128. ZHOU W, Brown JM, Bajaj NS, Chandra A, et al
    Hypertensive coronary microvascular dysfunction: a subclinical marker of end organ damage and heart failure.
    Eur Heart J. 2020 Mar 28. pii: 5813079. doi: 10.1093.
    >> Share

  129. DOCHERTY KF, Jhund PS, Inzucchi SE, Kober L, et al
    Effects of dapagliflozin in DAPA-HF according to background heart failure therapy.
    Eur Heart J. 2020 Mar 28. pii: 5813081. doi: 10.1093.
    >> Share

  130. VAN DER LINGEN ACJ, Allaart CP
    The role of implantable cardioverter-defibrillators in New York Heart Class I heart failure patients: do not abandon the asymptomatic just yet.
    Eur Heart J. 2020 Mar 25. pii: 5811615. doi: 10.1093.
    >> Share

  131. GOLDENBERG I, Huang DT, Nielsen JC
    The role of implantable cardioverter-defibrillators in asymptomatic patients with left ventricular dysfunction.
    Eur Heart J. 2020 Mar 25. pii: 5811613. doi: 10.1093.
    >> Share

  132. LUSCHER TF
    Ejection fraction to classify heart failure: are we using the right thing?
    Eur Heart J. 2020;41:1219-1222.
    >> Share

  133. MOTIEJUNAITE J, Akiyama E, Cohen-Solal A, Maggioni AP, et al
    The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions.
    Eur Heart J. 2020 Mar 3. pii: 5775572. doi: 10.1093.
    >> Share

  134. SLIWA K
    Heart failure can affect everyone: the ESC Geoffrey Rose lecture.
    Eur Heart J. 2020 Mar 2. pii: 5771280. doi: 10.1093.
    >> Share

  135. BOHM M, Ferreira JP, Mahfoud F, Duarte K, et al
    Myocardial reperfusion reverses the J-curve association of cardiovascular risk and diastolic blood pressure in patients with left ventricular dysfunction and heart failure after myocardial infarction: insights from the EPHESUS trial.
    Eur Heart J. 2020 Mar 2. pii: 5771273. doi: 10.1093.
    >> Share

  136. MESSERLI FH, Bangalore S, Messerli AW, Raber L, et al
    The muddy waters of the J-curve and coronary revascularization.
    Eur Heart J. 2020 Mar 2. pii: 5771269. doi: 10.1093.
    >> Share

    February 2020
  137. JAMALYAN S
    Surgical obesity treatment and the risk of heart failure: the possible mechanisms of interaction and diagnostic accuracy.
    Eur Heart J. 2020 Feb 24. pii: 5753975. doi: 10.1093.
    >> Share

  138. AZAR RR, Abdelmassih T
    Innovation in Heart Failure: from Pills to Devices.
    Eur Heart J. 2020;41:906-907.
    >> Share

  139. VAN WOERDEN G, van Veldhuisen SL, Rienstra M
    Incident heart failure risk after bariatric surgery: the role of epicardial fat.
    Eur Heart J. 2020 Feb 20. pii: 5741377. doi: 10.1093.
    >> Share

    January 2020
  140. ZHOU Y, Wen J, Nie J
    How much can acute heart failure patients with low basic blood pressure (systolic blood pressure 90-100 mmHg) benefit from the use of vasodilators?
    Eur Heart J. 2020 Jan 10. pii: 5700445. doi: 10.1093.
    >> Share

  141. CLELAND JGF, Lyon AR, McDonagh T, McMurray JJV, et al
    The year in cardiology: heart failure.
    Eur Heart J. 2020 Jan 6. pii: 5694316. doi: 10.1093.
    >> Share

  142. MCMURRAY JJV, Solomon SD, Docherty KF, Jhund PS, et al
    The Dapagliflozin And Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context.
    Eur Heart J. 2020 Jan 3. pii: 5695523. doi: 10.1093.
    >> Share

    December 2019
  143. COHEN-SOLAL A
    Iron deficiency in heart failure: why so frequent and which mechanisms?
    Eur Heart J. 2019 Dec 20. pii: 5682455. doi: 10.1093.
    >> Share

  144. MALMBORG M, Schmiegelow MDS, Norgaard CH, Munch A, et al
    Does type 2 diabetes confer higher relative rates of cardiovascular events in women compared with men?
    Eur Heart J. 2019 Dec 20. pii: 5682397. doi: 10.1093.
    >> Share

  145. SCHOU M, Kober L
    Sudden death in heart failure: do we understand what we observe?
    Eur Heart J. 2019 Dec 10. pii: 5671749. doi: 10.1093.
    >> Share

  146. LAM CSP, Arnott C, Beale AL, Chandramouli C, et al
    Sex differences in heart failure.
    Eur Heart J. 2019 Dec 4. pii: 5652224. doi: 10.1093.
    >> Share

    November 2019
  147. BARRA S, Providencia R, Narayanan K, Boveda S, et al
    Time trends in sudden cardiac death risk in heart failure patients with cardiac resynchronization therapy: a systematic review.
    Eur Heart J. 2019 Nov 21. pii: 5637310. doi: 10.1093.
    >> Share

  148. LUSCHER TF
    Optimizing heart failure management: anticoagulation, diuretic withdrawal, iron substitution, and novel inotropes.
    Eur Heart J. 2019;40:3579-3582.
    >> Share

  149. GOLDENBERG I, Huang DT, Nielsen JC
    The role of implantable cardioverter-defibrillators and sudden cardiac death prevention: indications, device selection, and outcome.
    Eur Heart J. 2019 Nov 12. pii: 5622905. doi: 10.1093.
    >> Share

  150. OMLAND T
    Targeting the endothelin system: a step towards a precision medicine approach in heart failure with preserved ejection fraction?
    Eur Heart J. 2019 Nov 4. pii: 5612120. doi: 10.1093.
    >> Share

    October 2019
  151. NG ACT, Bax JJ
    Hyperdynamic left ventricular function and the prognostic implications for heart failure with preserved ejection fraction.
    Eur Heart J. 2019 Oct 25. pii: 5607286. doi: 10.1093.
    >> Share

  152. HONARBAKHSH S, Prabhu S, Hunter RJ
    With our powers combined: Does the pooled analysis of existing randomized data regarding treatment of atrial fibrillation in heart failure settle the case for catheter ablation?
    Eur Heart J. 2019 Oct 22. pii: 5602553. doi: 10.1093.
    >> Share

  153. REDDY YNV, Obokata M, Wiley B, Koepp KE, et al
    The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction.
    Eur Heart J. 2019 Oct 14. pii: 5586988. doi: 10.1093.
    >> Share

  154. RICHTER S, Di Biase L, Hindricks G
    Atrial fibrillation ablation in heart failure: it's not all about Starling my darling.
    Eur Heart J. 2019 Oct 3. pii: 5580540. doi: 10.1093.
    >> Share

    September 2019
  155. FELKER GM
    Must I keep taking all these medicines? Optimizing diuretics in chronic heart failure.
    Eur Heart J. 2019 Sep 27. pii: 5575243. doi: 10.1093.
    >> Share

  156. CHATHA SR, Westwood M, Moon JC, Captur G, et al
    New-onset heart failure: free-breathing motion-corrected late gadolinium enhancement rescues the endomyocardial fibrosis diagnosis.
    Eur Heart J. 2019 Sep 27. pii: 5575240. doi: 10.1093.
    >> Share

  157. VAN DER WAL HH, Grote Beverborg N, Dickstein K, Anker SD, et al
    Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use.
    Eur Heart J. 2019 Sep 26. pii: 5574384. doi: 10.1093.
    >> Share

  158. WIJTVLIET EPJP, Tieleman RG, van Gelder IC, Pluymaekers NAHA, et al
    Nurse-led vs. usual-care for atrial fibrillation.
    Eur Heart J. 2019 Sep 23. pii: 5572602. doi: 10.1093.
    >> Share

  159. MARTIN AC, Hemery Y, Godier A
    Comment to "The year in cardiology 2018: heart failure".
    Eur Heart J. 2019 Sep 18. pii: 5571447. doi: 10.1093.
    >> Share

  160. OBOKATA M, Kane GC, Reddy YNV, Melenovsky V, et al
    The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction.
    Eur Heart J. 2019 Sep 12. pii: 5568303. doi: 10.1093.
    >> Share

    August 2019
  161. PIESKE B, Tschope C, de Boer RA, Fraser AG, et al
    How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
    Eur Heart J. 2019 Aug 31. pii: 5557740. doi: 10.1093.
    >> Share

  162. TAYAL B, Fruelund P, Sogaard P, Riahi S, et al
    Incidence of heart failure after pacemaker implantation: a nationwide Danish Registry-based follow-up study.
    Eur Heart J. 2019 Aug 26. pii: 5554632. doi: 10.1093.
    >> Share

  163. ROHDE LE, Rover MM, Figueiredo Neto JA, Danzmann LC, et al
    Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial.
    Eur Heart J. 2019 Aug 19. pii: 5551388. doi: 10.1093.
    >> Share

  164. MICHOU E, Fahrni G, Mueller C
    Quantifying heart failure using natriuretic peptides may help the HEART team in decision-making.
    Eur Heart J. 2019 Aug 19. pii: 5551384. doi: 10.1093.
    >> Share

  165. PACKER M
    What causes sudden death in patients with chronic heart failure and a reduced ejection fraction?
    Eur Heart J. 2019 Aug 7. pii: 5544750. doi: 10.1093.
    >> Share

  166. MCINTYRE WF, Connolly SJ, Wang J, Masiero S, et al
    Thromboembolic events around the time of cardioversion for atrial fibrillation in patients receiving antiplatelet treatment in the ACTIVE trials.
    Eur Heart J. 2019 Aug 4. pii: 5543556. doi: 10.1093.
    >> Share

  167. MAGGIONI AP, Andreotti F
    Stroke prevention by low-dose anticoagulation in patients with heart failure and sinus rhythm: is it worth the effort?
    Eur Heart J. 2019 Aug 1. pii: 5542639. doi: 10.1093.
    >> Share

    July 2019
  168. HOFMANN C, Volkers M, Katus HA
    Targeting coagulation in heart failure with preserved ejection fraction and cardiac fibrosis.
    Eur Heart J. 2019 Jul 19. pii: 5536327. doi: 10.1093.
    >> Share

  169. CHEN S, Purerfellner H, Meyer C, Acou WJ, et al
    Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation: a stratified pooled analysis of randomized data.
    Eur Heart J. 2019 Jul 11. pii: 5531275. doi: 10.1093.
    >> Share

  170. WATSON WD
    Reply to the commentary: Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF.
    Eur Heart J. 2019 Jul 10. pii: 5530696. doi: 10.1093.
    >> Share

  171. GHIMIRE A, Fine N, Ezekowitz JA, Howlett J, et al
    Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study.
    Eur Heart J. 2019;40:2110-2117.
    >> Share

    June 2019
  172. CLELAND JGF, Hindricks G, Petrie M
    The shocking lack of evidence for implantable cardioverter defibrillators for heart failure; with or without cardiac resynchronization.
    Eur Heart J. 2019 Jun 30. pii: 5525356. doi: 10.1093.
    >> Share

  173. HAMMERSLEY D, Halliday BP, Prasad SK
    Can we turn heart failure into heart success by studying myocardial remission?
    Eur Heart J. 2019 Jun 28. pii: 5524810. doi: 10.1093.
    >> Share

  174. MEHRA MR, Vaduganathan M, Fu M, Ferreira JP, et al
    A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial
    Eur Heart J. 2019 Jun 25. pii: 5522950. doi: 10.1093.
    >> Share

  175. REDDY YNV, Borlaug BA, O'Connor CM, Gersh BJ, et al
    Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions.
    Eur Heart J. 2019 Jun 14. pii: 5519089. doi: 10.1093.
    >> Share

  176. FINER N
    Weight loss for patients with obesity and heart failure.
    Eur Heart J. 2019 Jun 10. pii: 5513287. doi: 10.1093.
    >> Share

  177. GENTILLE LORENTE DI
    Coconut atrium: a rare entity to cause pulmonary hypertension.
    Eur Heart J. 2019 Jun 4. pii: 5510776. doi: 10.1093.
    >> Share

    May 2019
  178. PACKER M
    Are healthcare systems now ready to adopt sacubitril/valsartan as the preferred approach to inhibiting the renin-angiotensin system in chronic heart failure? The culmination of a 20-year journey.
    Eur Heart J. 2019 May 23. pii: 5497835. doi: 10.1093.
    >> Share

  179. MORROW DA, Velazquez EJ, DeVore AD, Prescott MF, et al
    Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial.
    Eur Heart J. 2019 May 15. pii: 5489800. doi: 10.1093.
    >> Share

  180. JAMALY S, Carlsson L, Peltonen M, Jacobson P, et al
    Surgical obesity treatment and the risk of heart failure.
    Eur Heart J. 2019 May 14. pii: 5489332. doi: 10.1093.
    >> Share

  181. PACKER M
    Effect of catheter ablation on pre-existing abnormalities of left atrial systolic, diastolic, and neurohormonal functions in patients with chronic heart failure and atrial fibrillation.
    Eur Heart J. 2019 May 12. pii: 5488510. doi: 10.1093.
    >> Share

    April 2019
  182. SKELIN M, Lucijanic M, Javor E
    The possible role of insulin and glucagon in patients with heart failure and Type 2 diabetes.
    Eur Heart J. 2019 Apr 28. pii: 5481181. doi: 10.1093.
    >> Share

  183. BERTERO E, Sequeira V, Heymans S, Maack C, et al
    Response to 'The possible role of insulin and glucagon in patients with heart failure and Type 2 diabetes'.
    Eur Heart J. 2019 Apr 28. pii: 5481175. doi: 10.1093.
    >> Share

  184. VON HAEHLING S, Doehner W, Anker SD
    The evolving obesity paradigm story: from heart failure to atrial fibrillation.
    Eur Heart J. 2019 Apr 21. pii: 5476266. doi: 10.1093.
    >> Share

  185. PRAZ F, Grasso C, Taramasso M, Baumbach A, et al
    Mitral regurgitation in heart failure: time for a rethink.
    Eur Heart J. 2019 Apr 21. pii: 5475839. doi: 10.1093.
    >> Share

  186. TRIPOSKIADIS F, Butler J, Abboud FM, Armstrong PW, et al
    The continuous heart failure spectrum: moving beyond an ejection fraction classification.
    Eur Heart J. 2019 Apr 8. pii: 5431175. doi: 10.1093.
    >> Share

    February 2019
  187. CLELAND JGF, van Veldhuisen DJ, Ponikowski P
    The year in cardiology 2018: heart failure.
    Eur Heart J. 2019;40:651-661.
    >> Share

  188. VAN DEN BERG MP, Mulder BA, Klaassen SHC, Maass AH, et al
    Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis.
    Eur Heart J. 2019 Feb 8. pii: 5310346. doi: 10.1093.
    >> Share

  189. HILFIKER-KLEINER D, Ardehali H, Fischmeister R, Burridge P, et al
    Late onset heart failure after childhood chemotherapy.
    Eur Heart J. 2019 Feb 7. pii: 5309990. doi: 10.1093.
    >> Share


  190. Heart Failure and Sepsis: Cardiologists have developed a new 'risk profile' tool to identify heart failure patients at risk of dying from sepsis. Mark Nicholls reports.
    Eur Heart J. 2019;40:409-410.
    >> Share

    January 2019
  191. TARAMASSO M, Gavazzoni M, Maisano F
    Is tricuspid regurgitation a prognostic interventional target or is it just an indicator of worst prognosis in heart failure patients?
    Eur Heart J. 2019 Jan 25. pii: 5301478. doi: 10.1093.
    >> Share

  192. GORTER TM, van Veldhuisen DJ, Voors AA
    Rapid right-sided deterioration in heart failure with preserved ejection fraction.
    Eur Heart J. 2019 Jan 4. pii: 5273477. doi: 10.1093.
    >> Share

  193. WOJAKOWSKI W, Baumgartner H
    The year in cardiology 2018: valvular heart disease.
    Eur Heart J. 2019 Jan 2. pii: 5265301. doi: 10.1093.
    >> Share

  194. CHAO TF, Lip GYH, Lin YJ, Chang SL, et al
    Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities.
    Eur Heart J. 2019 Jan 2. pii: 5272355. doi: 10.1093.
    >> Share

    December 2018
  195. HALLIDAY BP, Pennell DJ
    Prediction and prevention of heart failure in high-risk elderly patients.
    Eur Heart J. 2018 Dec 27. pii: 5263767. doi: 10.1093.
    >> Share

  196. LUSCHER TF
    Personalized approaches to heart failure: age, acute presentation, and comorbidities.
    Eur Heart J. 2018;39:4223-4226.
    >> Share

  197. RICHTER S, Di Biase L, Hindricks G
    Atrial fibrillation ablation in heart failure.
    Eur Heart J. 2018 Dec 14. pii: 5248225. doi: 10.1093.
    >> Share

  198. TROMP J, Ouwerkerk W, Demissei BG, Anker SD, et al
    Novel endotypes in heart failure: effects on guideline-directed medical therapy.
    Eur Heart J. 2018 Dec 13. pii: 5245844. doi: 10.1093.
    >> Share

  199. OBOKATA M, Reddy YNV, Melenovsky V, Pislaru S, et al
    Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction.
    Eur Heart J. 2018 Dec 12. pii: 5240922. doi: 10.1093.
    >> Share

    November 2018
  200. TINI G, Olivotto I, Canepa M
    Letter regarding the article 'Heart failure with preserved ejection fraction: from mechanisms to therapies' by Lam and colleagues.
    Eur Heart J. 2018 Nov 29. pii: 5219619. doi: 10.1093.
    >> Share


  201. Corrigendum to: Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF.
    Eur Heart J. 2018 Nov 23. pii: 5203433. doi: 10.1093.
    >> Share


  202. Corrigendum to: Heart failure with preserved ejection fraction: from mechanisms to therapies.
    Eur Heart J. 2018 Nov 23. pii: 5203434. doi: 10.1093.
    >> Share

  203. SIONTIS KC, Yao X, Noseworthy PA
    Atrial fibrillation in heart failure syndromes: does it matter more in some than in others?
    Eur Heart J. 2018 Nov 20. pii: 5193438. doi: 10.1093.
    >> Share

  204. NISHIMURA M, Maisel AS
    Biomarkers: a window into the pathophysiology of atrial fibrillation in heart failure with reduced vs. preserved ejection fraction.
    Eur Heart J. 2018;39:3876-3878.
    >> Share

    October 2018
  205. BOERSMA LVA
    Biventricular pacing after AV-node ablation for atrial fibrillation with heart failure: something old and something new, future standard, or just for the few?
    Eur Heart J. 2018 Oct 25. pii: 5145027. doi: 10.1093.
    >> Share

  206. BEGGS SAS, Jhund PS, McMurray JJV
    Anticoagulation, atherothrombosis, and heart failure: lessons from COMMANDER-HF and CORONA.
    Eur Heart J. 2018 Oct 23. pii: 5143981. doi: 10.1093.
    >> Share

  207. SAVARESE G, Dahlstrom U, Vasko P, Pitt B, et al
    Association between renin-angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study.
    Eur Heart J. 2018 Oct 22. pii: 5142410. doi: 10.1093.
    >> Share

  208. WANG N, Fulcher J, Abeysuriya N, McGrady M, et al
    Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis.
    Eur Heart J. 2018 Oct 22. pii: 5142409. doi: 10.1093.
    >> Share

  209. FUDIM M, Ganesh A, Green C, Jones WS, et al
    Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF.
    Eur Heart J. 2018 Oct 20. pii: 5135328. doi: 10.1093.
    >> Share

  210. YANG XQ, Xiong T, Wang DX
    The potential multiple effects of beta3-adrenergic receptor agonists on the heart protection for patients with heart failure with preserved ejection fraction.
    Eur Heart J. 2018 Oct 17. pii: 5137111. doi: 10.1093.
    >> Share

  211. BALLIGAND JL
    Response to 'The potential multiple effects of beta3-adrenergic receptor agonists on the heart protection for patients with heart failure with preserved ejection fraction'.
    Eur Heart J. 2018 Oct 17. pii: 5137137. doi: 10.1093.
    >> Share

  212. PETROVIC J, Boricic I, Petrovic M, Ivanovic B, et al
    Endomyocardial fibrosis and unileaflet mitral valve: a fatal postpartum outcome.
    Eur Heart J. 2018 Oct 17. pii: 5137115. doi: 10.1093.
    >> Share

  213. ZAFRIR B, Lund LH, Laroche C, Ruschitzka F, et al
    Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry.
    Eur Heart J. 2018 Oct 15. pii: 5133012. doi: 10.1093.
    >> Share

  214. MAACK C, Lehrke M, Backs J, Heinzel FR, et al
    Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology.
    Eur Heart J. 2018 Oct 8. pii: 5123540. doi: 10.1093.
    >> Share

  215. HASIN T, Glikson M, Hasin Y
    The Heart Failure Unit At Shaare Zedek Hospital Medical Center.
    Eur Heart J. 2018;39:3491-3492.
    >> Share

  216. HASIN T, Zalut T, Hasin Y
    Managing the Patient with Heart Failure in the Emergency Department.
    Eur Heart J. 2018;39:3493-3495.
    >> Share

    September 2018
  217. SZUMMER K, Wallentin L, Lindhagen L, Alfredsson J, et al
    Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014.
    Eur Heart J. 2018 Sep 19. pii: 5103432. doi: 10.1093.
    >> Share

  218. ESHAK N, Abdelnaby M, Shehata H, Ziada K, et al
    A case of fibrosing mediastinitis complicated by pulmonary hypertension and right-sided heart failure.
    Eur Heart J. 2018 Sep 7. pii: 5092489. doi: 10.1093.
    >> Share

    August 2018
  219. SHAH SJ, Lam CSP, Svedlund S, Saraste A, et al
    Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF.
    Eur Heart J. 2018 Aug 27. pii: 5077831. doi: 10.1093.
    >> Share

  220. GUSTAFSSON F, Shaw S, Lavee J, Saeed D, et al
    Six-month outcomes after treatment of advanced heart failure with a full magnetically levitated continuous flow left ventricular assist device: report from the ELEVATE registry.
    Eur Heart J. 2018 Aug 27. pii: 5084900. doi: 10.1093.
    >> Share

  221. WEI J, Nelson MD, Sharif B, Shufelt C, et al
    Why do we care about coronary microvascular dysfunction and heart failure with preserved ejection fraction: addressing knowledge gaps for evidence-based guidelines.
    Eur Heart J. 2018 Aug 27. pii: 5079249. doi: 10.1093.
    >> Share

  222. SANTEMA BT, Kloosterman M, Van Gelder IC, Mordi I, et al
    Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction.
    Eur Heart J. 2018 Aug 22. pii: 5077588. doi: 10.1093.
    >> Share

  223. CHAGGAR P, Squire I, Kalra PR
    British Society of Heart Failure.
    Eur Heart J. 2018;39:2773-2774.
    >> Share

  224. LUSCHER TF
    Heart failure with preserved ejection fraction: unravelling an enigma.
    Eur Heart J. 2018;39:2763-2766.
    >> Share

  225. AMSTEIN R
    The New Postgraduate Course in Heart Failure.
    Eur Heart J. 2018;39:2775-2777.
    >> Share

  226. POLOVINA M, Hindricks G, Maggioni A, Piepoli M, et al
    Association of metabolic syndrome with non-thromboembolic adverse cardiac outcomes in patients with atrial fibrillation.
    Eur Heart J. 2018 Aug 7. pii: 5067645. doi: 10.1093.
    >> Share

  227. RUSH CJ, Campbell RT, Jhund PS, Petrie MC, et al
    Association is not causation: treatment effects cannot be estimated from observational data in heart failure.
    Eur Heart J. 2018 Aug 1. pii: 5063542. doi: 10.1093.
    >> Share

    July 2018
  228. TAKAHAMA H, Minamino N, Izumi C
    Plasma soluble neprilysin levels are unchanged during recovery after decompensation of heart failure: a matter of the magnitude of the changes in systemic haemodynamics?
    Eur Heart J. 2018 Jul 27. pii: 5060561. doi: 10.1093.
    >> Share

  229. TOPILSKY Y, Inojosa JM, Benfari G, Vaturi O, et al
    Clinical presentation and outcome of tricuspid regurgitation in patients with systolic dysfunction.
    Eur Heart J. 2018 Jul 27. pii: 5060565. doi: 10.1093.
    >> Share

  230. VAN EMPEL V, Brunner-La Rocca HP
    Helping to understand heart failure with preserved ejection fraction.
    Eur Heart J. 2018 Jul 9. pii: 5050878. doi: 10.1093.
    >> Share

    June 2018
  231. GORTER TM, Obokata M, Reddy YNV, Melenovsky V, et al
    Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease.
    Eur Heart J. 2018 Jun 26. pii: 5045545. doi: 10.1093.
    >> Share

  232. WEBER T, Chirinos JA
    Pulsatile arterial haemodynamics in heart failure.
    Eur Heart J. 2018 Jun 26. pii: 5045547. doi: 10.1093.
    >> Share

  233. PACKER M
    Questioning the obvious: does dyspnoea really matter in heart failure?
    Eur Heart J. 2018 Jun 22. pii: 5043114. doi: 10.1093.
    >> Share

  234. LAM CSP, Voors AA, de Boer RA, Solomon SD, et al
    Heart failure with preserved ejection fraction: from mechanisms to therapies.
    Eur Heart J. 2018 Jun 13. pii: 5037246. doi: 10.1093.
    >> Share

    May 2018
  235. LUSCHER TF
    Mechanisms and outcomes of heart failure: from HFpEF, HFmrEF, and HFrEF to transplantation.
    Eur Heart J. 2018;39:1749-1753.
    >> Share

  236. ANGERMANN CE, Frantz S, Maack C
    The Comprehensive Heart Failure Centre in Wurzburg, Germany.
    Eur Heart J. 2018;39:1757-1760.
    >> Share

  237. SWOBODA PP, Plein S
    Heart failure in Diabetic patients.
    Eur Heart J. 2018;39:1755-1757.
    >> Share

  238. OBOKATA M, Olson TP, Reddy YNV, Melenovsky V, et al
    Haemodynamics, dyspnoea, and pulmonary reserve in heart failure with preserved ejection fraction.
    Eur Heart J. 2018 May 19. pii: 4999864. doi: 10.1093.
    >> Share

    March 2018
  239. VADUGANATHAN M, Solomon SD
    Expanding the global borders of heart failure: the SHOP and PEOPLE studies.
    Eur Heart J. 2018 Mar 22. pii: 4951580. doi: 10.1093.
    >> Share

  240. FONSECA C
    A Heart Failure Clinic.
    Eur Heart J. 2018;39:826-828.
    >> Share

  241. BEGGS S, Gardner R
    Thirty years of heart failure.
    Eur Heart J. 2018;39:824-826.
    >> Share

    February 2018
  242. YAMAMOTO M, Seo Y, Ishizu T, Aonuma K, et al
    Reversible aortic valve stenosis with Loffler endocarditis.
    Eur Heart J. 2018 Feb 26. pii: 4911114. doi: 10.1093.
    >> Share

  243. EL HARANE N, Kervadec A, Bellamy V, Pidial L, et al
    Acellular therapeutic approach for heart failure: in vitro production of extracellular vesicles from human cardiovascular progenitors.
    Eur Heart J. 2018 Feb 6. pii: 4840711. doi: 10.1093.
    >> Share

  244. RIENSTRA M, Hobbelt AH, Alings M, Tijssen JGP, et al
    Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial.
    Eur Heart J. 2018 Feb 1. pii: 4786620. doi: 10.1093.
    >> Share

    January 2018
  245. LAM CSP, Gamble GD, Ling LH, Sim D, et al
    Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study.
    Eur Heart J. 2018 Jan 29. pii: 4829677. doi: 10.1093.
    >> Share

  246. MEHLUM MH, Liestol K, Kjeldsen SE, Julius S, et al
    Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks.
    Eur Heart J. 2018 Jan 20. pii: 4815726. doi: 10.1093.
    >> Share

  247. NELSON MD, Wei J, Bairey Merz CN
    Coronary microvascular dysfunction and heart failure with preserved ejection fraction as female-pattern cardiovascular disease: the chicken or the egg?
    Eur Heart J. 2018 Jan 16. pii: 4811982. doi: 10.1093.
    >> Share

  248. HEINZMANN D, Seizer P
    Mitochondria in heart failure: EMID-sign.
    Eur Heart J. 2018 Jan 3. pii: 4786075. doi: 10.1093.
    >> Share

  249. LUND LH, Kober L, Swedberg K, Ruschitzka F, et al
    The year in cardiology 2017: heart failure.
    Eur Heart J. 2018 Jan 2. pii: 4774532. doi: 10.1093.
    >> Share

  250. LUSCHER TF
    Heart failure subgroups: HFrEF, HFmrEF, and HFpEF with or without mitral regurgitation.
    Eur Heart J. 2018;39:1-4.
    >> Share

  251. PACKER M
    The Future Treatment of Heart Failure?
    Eur Heart J. 2018;39:5-7.
    >> Share

    December 2017
  252. TAQUETI VR, Solomon SD, Shah AM, Desai AS, et al
    Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction.
    Eur Heart J. 2017 Dec 26. pii: 4775060. doi: 10.1093.
    >> Share

  253. BERMEJO J, Yotti R, Garcia-Orta R, Sanchez-Fernandez PL, et al
    Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial.
    Eur Heart J. 2017 Dec 21. pii: 4769387. doi: 10.1093.
    >> Share

  254. ARRIGO M, Vodovar N, Nougue H, Sadoune M, et al
    The heart regulates the endocrine response to heart failure: cardiac contribution to circulating neprilysin.
    Eur Heart J. 2017 Dec 13. pii: 4735305. doi: 10.1093.
    >> Share

  255. WILCOX JE, Mann DL
    Beta-blockers for the treatment of heart failure with a mid-range ejection fraction: deja-vu all over again?
    Eur Heart J. 2017 Dec 11. pii: 4728646. doi: 10.1093.
    >> Share

    November 2017
  256. MASIP J, Peacock WF, Price S, Cullen L, et al
    Indications and practical approach to non-invasive ventilation in acute heart failure.
    Eur Heart J. 2017 Nov 26. pii: 4654494. doi: 10.1093.
    >> Share

  257. GRASSI G, Mancia G
    'Keep an eye' on the heart: retinal microcirculation disarray in congestive heart failure.
    Eur Heart J. 2017 Nov 23. pii: 4654727. doi: 10.1093.
    >> Share

  258. NICHOLLS M
    Finn Waagstein MD PhD: Finn Waagstein reflects on his work and research which saw beta-blockers revolutionise the treatment of heart failure patients. Mark Nicholls reports.
    Eur Heart J. 2017;38:3249-3250.
    >> Share

  259. ROSANO GMC
    HFA Congress 2017: The Congress of the Heart Failure Association of the ESC: a continuous success story, the result of a long-term vision.
    Eur Heart J. 2017;38:3042-3043.
    >> Share

  260. TOFIELD A
    Heart Failure Congress sets record: The 2017 ESC Heart Failure Association Congress had a new record number of submissions for original science.
    Eur Heart J. 2017;38:3041.
    >> Share

    October 2017
  261. NAGELE MP, Barthelmes J, Ludovici V, Cantatore S, et al
    Retinal microvascular dysfunction in heart failure.
    Eur Heart J. 2017 Oct 21. doi: 10.1093.
    >> Share

  262. CLELAND JGF, Bunting KV, Flather MD, Altman DG, et al
    Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials.
    Eur Heart J. 2017 Oct 10. doi: 10.1093.
    >> Share

  263. LUSCHER TF
    Special issues in heart failure: pulmonary hypertension, deranged potassium levels, and haemodynamic profiles.
    Eur Heart J. 2017;38:2857-2859.
    >> Share

  264. BLANTON RM
    What can haemodynamic profiles teach us about heart failure in the paediatric population?
    Eur Heart J. 2017;38:2910-2911.
    >> Share

  265. PITT B, Rossignol P
    Serum potassium in patients with chronic heart failure: once we make a U-turn where should we go?
    Eur Heart J. 2017;38:2897-2899.
    >> Share

  266. CHEN S, Dykes JC, McElhinney DB, Gajarski RJ, et al
    Haemodynamic profiles of children with end-stage heart failure.
    Eur Heart J. 2017;38:2900-2909.
    >> Share

  267. ALDAHL M, Jensen AC, Davidsen L, Eriksen MA, et al
    Associations of serum potassium levels with mortality in chronic heart failure patients.
    Eur Heart J. 2017;38:2890-2896.
    >> Share

    September 2017
  268. SCHMIEDER RE, Wagner F, Mayr M, Delles C, et al
    The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
    Eur Heart J. 2017 Sep 27. doi: 10.1093.
    >> Share

    August 2017
  269. SZUMMER K, Wallentin L, Lindhagen L, Alfredsson J, et al
    Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014.
    Eur Heart J. 2017 Aug 29. doi: 10.1093.
    >> Share

  270. FITCHETT D, Butler J, van de Borne P, Zinman B, et al
    Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME(R) trial.
    Eur Heart J. 2017 Aug 28. doi: 10.1093.
    >> Share

  271. LUSCHER TF
    Update on heart failure: biomarkers, intensive therapy, remote monitoring, and cardiomyocyte renewal.
    Eur Heart J. 2017;38:2315-2317.
    >> Share

  272. DE BOER RA, Meems LMG, van Veldhuisen DJ
    Vitamin D supplementation in heart failure: case closed?
    Eur Heart J. 2017;38:2287-2289.
    >> Share

    July 2017
  273. DE WAHA S, Patel MR, Granger CB, Ohman EM, et al
    Relationship between microvascular obstruction and adverse events following primary primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials.
    Eur Heart J. 2017 Jul 28. doi: 10.1093.
    >> Share

  274. GOLIASCH G, Bartko PE, Pavo N, Neuhold S, et al
    Refining the prognostic impact of functional mitral regurgitation in chronic heart failure.
    Eur Heart J. 2017 Jul 25. doi: 10.1093.
    >> Share

    June 2017
  275. LUSCHER TF
    Risk factors for chronic heart failure: obesity, renal dysfunction, arteriovenous fistulas, and amyloid deposition.
    Eur Heart J. 2017;38:1857-1860.
    >> Share

  276. ROURA S, Galvez-Monton C, Lupon J, Bayes-Genis A, et al
    Biotherapies and biomarkers for cardiovascular diseases: A 15-year journey at the ICREC (Heart Failure and Cardiac Regeneration) Research Laboratory in Barcelona, Spain.
    Eur Heart J. 2017;38:1784-1786.
    >> Share

  277. CHATTERJEE NA, Singh JP
    Making sense of remote monitoring studies in heart failure.
    Eur Heart J. 2017 Jun 13. doi: 10.1093.
    >> Share

  278. SUGIHARA S, Burnett JC Jr
    BLAST-AHF: insights into biased AT1 ligands and heart failure. Beginning of the end or end of the beginning?
    Eur Heart J. 2017 Jun 1. doi: 10.1093.
    >> Share

    May 2017
  279. MORGAN JM, Kitt S, Gill J, McComb JM, et al
    Remote management of heart failure using implantable electronic devices.
    Eur Heart J. 2017 May 27. doi: 10.1093.
    >> Share

  280. SCUFFHAM PA, Ball J, Horowitz JD, Wong C, et al
    Standard vs. intensified management of heart failure to reduce healthcare costs: results of a multicentre, randomized controlled trial.
    Eur Heart J. 2017 May 20. doi: 10.1093.
    >> Share

  281. ZITTERMANN A, Ernst JB, Prokop S, Fuchs U, et al
    Effect of vitamin D on all-cause mortality in heart failure (EVITA): a 3-year randomized clinical trial with 4000 IU vitamin D daily.
    Eur Heart J. 2017 May 12. doi: 10.1093.
    >> Share

  282. SCHUPKE S, Mehilli J
    Less myocardial scar but greater propensity for heart failure: another gender paradox in myocardial infarction.
    Eur Heart J. 2017 May 5. doi: 10.1093.
    >> Share

    April 2017
  283. PANG PS, Butler J, Collins SP, Cotter G, et al
    Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF).
    Eur Heart J. 2017 Apr 27. doi: 10.1093.
    >> Share

  284. BORLAUG BA, Obokata M
    Is it time to recognize a new phenotype? Heart failure with preserved ejection fraction with pulmonary vascular disease.
    Eur Heart J. 2017 Apr 17. doi: 10.1093.
    >> Share

  285. LUSCHER TF
    From systemic and pulmonary hypertension to heart failure: novel drugs and devices.
    Eur Heart J. 2017;38:1087-1090.
    >> Share

  286. CLELAND JGF, Mueller C
    What can we learn from SOCRATES: more questions than answers?
    Eur Heart J. 2017;38:1128-1131.
    >> Share

  287. MCDIARMID AK, Pellicori P, Cleland JG, Plein S, et al
    Taxonomy of segmental myocardial systolic dysfunction.
    Eur Heart J. 2017;38:942-954.
    >> Share

    March 2017
  288. PIESKE B, Maggioni AP, Lam CS, Pieske-Kraigher E, et al
    Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
    Eur Heart J. 2017 Mar 22. doi: 10.1093.
    >> Share

  289. MCCULLOUGH PA, Rios A, Smith B
    Dialysis fistulas and heart failure.
    Eur Heart J. 2017 Mar 17. doi: 10.1093.
    >> Share

  290. OUWERKERK W, Voors AA, Anker SD, Cleland JG, et al
    Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study.
    Eur Heart J. 2017 Mar 11. doi: 10.1093.
    >> Share

  291. LUSCHER TF
    Frontiers in heart failure: sodium, longitudinal strain, contractility sensor, fatal arrhythmias, and stroke.
    Eur Heart J. 2017;38:693-696.
    >> Share

  292. ABDUL-RAHIM AH, Perez AC, MacIsaac RL, Jhund PS, et al
    Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials.
    Eur Heart J. 2017;38:742-750.
    >> Share

  293. BAX JJ, Delgado V, Sogaard P, Singh JP, et al
    Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: a subanalysis of the randomized EchoCRT trial.
    Eur Heart J. 2017;38:720-726.
    >> Share

  294. STEPHAN VON BARDELEBEN R, Tamm A, Emrich T, Munzel T, et al
    Percutaneous transvenous direct annuloplasty of a human tricuspid valve using the Valtech Cardioband.
    Eur Heart J. 2017;38:690.
    >> Share

    February 2017

  295. Corrigendum to: Sacubitril/valsartan and low blood pressure in heart failure with reduced ejection fraction [Eur Heart J 2017; doi:10.1093/eurheartj/ehx014].
    Eur Heart J. 2017 Feb 28. doi: 10.1093.
    >> Share

  296. MULLENS W, Verbrugge FH, Nijst P, Tang WH, et al
    Renal sodium avidity in heart failure: from pathophysiology to treatment strategies.
    Eur Heart J. 2017 Feb 23. doi: 10.1093.
    >> Share

  297. MATHUR A, Fernandez-Aviles F, Dimmeler S, Hauskeller C, et al
    The consensus of the Task Force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for the treatment of acute myocardial infarction and heart failure: update 2016.
    Eur Heart J. 2017 Feb 15. doi: 10.1093.
    >> Share

  298. BAYES-GENIS A, Voors AA, Zannad F, Januzzi JL, et al
    Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action.
    Eur Heart J. 2017 Feb 15. doi: 10.1093.
    >> Share

  299. BOHM M, Young R, Jhund PS, Solomon SD, et al
    Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
    Eur Heart J. 2017 Feb 1. doi: 10.1093.
    >> Share

  300. SINGH A, Laribi S, Teerlink JR, Mebazaa A, et al
    Agents with vasodilator properties in acute heart failure.
    Eur Heart J. 2017;38:317-325.
    >> Share

  301. LUSCHER TF
    An update on heart failure: from experimental findings to clinical trials.
    Eur Heart J. 2017;38:305-307.
    >> Share

  302. TOFIELD A
    Teenage weight and risk for adult heart failure.
    Eur Heart J. 2017;38:311-312.
    >> Share

  303. TOFIELD A
    End of the road for aliskiren in heart failure.
    Eur Heart J. 2017;38:312-313.
    >> Share


  304. Professor Jay Cohn a pioneer in heart failure.
    Eur Heart J. 2017;38:308-309.
    >> Share

  305. HARPER AR, Cowie MR
    Remote monitoring for heart failure: the story moves on.
    Eur Heart J. 2017;38:310-311.
    >> Share

    January 2017
  306. BRUNO RM, Taddei S
    Sacubril/valsartan and low blood pressure in heart failure with reduced ejection fraction.
    Eur Heart J. 2017 Jan 30. doi: 10.1093.
    >> Share

  307. HORCKMANS M, Ring L, Duchene J, Santovito D, et al
    Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype.
    Eur Heart J. 2017;38:187-197.
    >> Share

  308. LANDIN AM, Hare JM
    The quest for a successful cell-based therapeutic approach for heart failure.
    Eur Heart J. 2017 Jan 10. pii: ehw626. doi: 10.1093.
    >> Share

  309. BAVENDIEK U, Aguirre Davila L, Koch A, Bauersachs J, et al
    Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure.
    Eur Heart J. 2017 Jan 8. pii: ehw577. doi: 10.1093.
    >> Share

  310. CHATTERJEE NA, Borgquist R, Chang Y, Lewey J, et al
    Increasing sex differences in the use of cardiac resynchronization therapy with or without implantable cardioverter-defibrillator.
    Eur Heart J. 2017 Jan 8. pii: ehw598. doi: 10.1093.
    >> Share

  311. MAGGIONI AP, Ruschitzka F
    The year in cardiology 2016: heart failure.
    Eur Heart J. 2017 Jan 2. pii: ehw638. doi: 10.1093.
    >> Share

    December 2016
  312. MAISEL AS, Di Somma S
    Do we need another heart failure biomarker: focus on soluble suppression of tumorigenicity 2 (sST2).
    Eur Heart J. 2016 Dec 27. pii: ehw462. doi: 10.1093.
    >> Share

  313. NAKAMURA T, Masumoto A, Tahara N, Kuroda Y, et al
    Acute heart failure caused by mechanical valve leaflet dislodgment at the mitral position.
    Eur Heart J. 2016 Dec 23. pii: ehw521. doi: 10.1093.
    >> Share

  314. BARTUNEK J, Terzic A, Davison BA, Filippatos GS, et al
    Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial.
    Eur Heart J. 2016 Dec 23. pii: ehw543. doi: 10.1093.
    >> Share

  315. HOEPER MM, Lam CS, Vachiery JL, Bauersachs J, et al
    Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further researchdagger.
    Eur Heart J. 2016 Dec 23. pii: ehw597. doi: 10.1093.
    >> Share

  316. MINOIA C, Paolillo S
    Two weeks at Harvard, for two European heart failure trainees.
    Eur Heart J. 2016;37:3553-3554.
    >> Share

  317. PAOLILLO S
    The ESC Heart Failure Association postgraduate course in heart failure.
    Eur Heart J. 2016;37:3551-3552.
    >> Share

    November 2016
  318. AMMIRATI E, Burns JC, Moreo A, Daniels LB, et al
    Extreme giant aneurysms of three coronary arteries causing heart failure as late sequelae of Kawasaki disease.
    Eur Heart J. 2016.
    >> Share


  319. What the Heart Failure Congress means to the Heart Failure Association.
    Eur Heart J. 2016;37:3124-3126.
    >> Share


  320. First European advice launched for acute heart failure.
    Eur Heart J. 2016;37:3123-3124.
    >> Share


  321. What's new in the European Society of Cardiology 2016 Guidelines for the diagnosis and treatment of acute and chronic heart failure?
    Eur Heart J. 2016;37:3121-3122.
    >> Share

    October 2016
  322. CREA F, Bairey Merz CN, Beltrame JF, Kaski JC, et al
    The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift.
    Eur Heart J. 2016.
    >> Share

  323. DOCHERTY KF, Campbell RT, Jhund PS, Petrie MC, et al
    How robust are clinical trials in heart failure?
    Eur Heart J. 2016.
    >> Share

    September 2016
  324. JORGE C, Hiltrop N, Desmet W
    Heart failure with preserved ejection fraction: blame the veins....
    Eur Heart J. 2016.
    >> Share

  325. MOHSENI H, Kiran A, Khorshidi R, Rahimi K, et al
    Influenza vaccination and risk of hospitalization in patients with heart failure: a self-controlled case series study.
    Eur Heart J. 2016.
    >> Share

  326. JHUND PS
    Obesity and heart failure: when 'epidemics' collide.
    Eur Heart J. 2016 Sep 22. doi: 10.1093.
    >> Share

  327. FRADLEY MG
    The evolving field of cardio-oncology: beyond anthracyclines and heart failure.
    Eur Heart J. 2016;37:2740-2742.
    >> Share

  328. ZHABYEYEV P, Oudit GY
    Unravelling the molecular basis for cardiac iron metabolism and deficiency in heart failure.
    Eur Heart J. 2016.
    >> Share

  329. KOYAMA M, Yano T, Kikuchi K, Nagahara D, et al
    Lethal heart failure with anti-mitochondrial antibody: an arrhythmogenic right ventricular cardiomyopathy mimetic.
    Eur Heart J. 2016.
    >> Share


  330. The Acute Heart Failure Academy.
    Eur Heart J. 2016;37:2568-9.
    >> Share

  331. LUSCHER TF
    From heart failure to transplantation: genes, miRNAs, and biomarkers.
    Eur Heart J. 2016;37:2561-3.
    >> Share

    August 2016
  332. LUSCHER TF
    Atrial fibrillation and stroke: risk factors, anticoagulation, and left atrial appendage occluders.
    Eur Heart J. 2016;37:2443-5.
    >> Share

    April 2016
  333. SMISETH OA, Torp H, Opdahl A, Haugaa KH, et al
    Myocardial strain imaging: how useful is it in clinical decision making?
    Eur Heart J. 2016;37:1196-207.
    >> Share

  334. PATIL NP, Weymann A, Popov AF, Simon AR, et al
    Chest X-ray in cardiac illness: a tale of four decades.
    Eur Heart J. 2016;37:1243.
    >> Share

  335. SCHMIDT M, Lamberts M, Olsen AM, Fosboll E, et al
    Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology.
    Eur Heart J. 2016;37:1015-23.
    >> Share

    March 2016
  336. LUSCHER TF
    Update on hypertension: target blood pressure, comorbidities, and outcome.
    Eur Heart J. 2016;37:921-3.
    >> Share

    February 2016
  337. LOCH A, Geh DJ, Veriah RS
    Cardiac magnetic resonance imaging: a tool to diagnose parasitic infection?
    Eur Heart J. 2016;37:702.
    >> Share

  338. DWECK M, Chin C
    CardioPulse: Settling scores with a failing heart.
    Eur Heart J. 2016;37:433-4.
    >> Share

  339. WESTENBRINK BD, van Laake LW, Brugts JJ
    CardioPulse: The Postgraduate Course in Heart Failure.
    Eur Heart J. 2016;37:428-9.
    >> Share

  340. DIMARCO A, Mansoubi H, Tanner M
    An unusual cause of left ventricular hypertrophy.
    Eur Heart J. 2016;37:497.
    >> Share

  341. LECLERCQ C, Sadoul N, Mont L, Defaye P, et al
    Comparison of right ventricular septal pacing and right ventricular apical pacing in patients receiving cardiac resynchronization therapy defibrillators: the SEPTAL CRT Study.
    Eur Heart J. 2016;37:473-83.
    >> Share

  342. STONE GW, Chung ES, Stancak B, Svendsen JH, et al
    Peri-infarct zone pacing to prevent adverse left ventricular remodelling in patients with large myocardial infarction.
    Eur Heart J. 2016;37:484-93.
    >> Share

    January 2016
  343. RABER L, Piccolo R
    CardioPulse: Different bleeding scores and which one should we use?
    Eur Heart J. 2016;37:327-31.
    >> Share

  344. NICHOLLS M
    CardioPulse: Cyclosporine to reduce myocardial infarction injury?
    Eur Heart J. 2016;37:210-1.
    >> Share

    December 2015
  345. IUNG B, Doco-Lecompte T, Chocron S, Strady C, et al
    Cardiac surgery during the acute phase of infective endocarditis: discrepancies between European Society of Cardiology guidelines and practices.
    Eur Heart J. 2015.
    >> Share

    November 2015
  346. PULS M, Lubos E, Boekstegers P, von Bardeleben RS, et al
    One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry.
    Eur Heart J. 2015.
    >> Share

    August 2015
  347. MALASA M, Werner N, Nickenig G, Hammerstingl C, et al
    Transcatheter tricuspid valve repair in a patient with isolated functional tricuspid valve regurgitation.
    Eur Heart J. 2015.
    >> Share

  348. CHATTERJEE NA, Roka A, Lubitz SA, Gold MR, et al
    Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review.
    Eur Heart J. 2015.
    >> Share

    July 2015
  349. CORRADO D, Wichter T, Link MS, Hauer R, et al
    Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement.
    Eur Heart J. 2015.
    >> Share

    June 2015
  350. YSSAP J, Lebreton G, Hoen B, Larifla L, et al
    Infected left ventricular thrombus revealing an unrecognized coronary dissection after blunt chest trauma, treated with emergency heart transplantation.
    Eur Heart J. 2015.
    >> Share

  351. FANKHAUSER CD, Nietlispach F, Emmert MY, Maisano F, et al
    Antegrade valve embolization after transcatheter treatment for pure aortic regurgitation.
    Eur Heart J. 2015.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016